•
Sep 30, 2022

Quanterix Q3 2022 Earnings Report

Quanterix's Q3 2022 operating results were released, revealing revenue flat compared to the previous year excluding RADx, and a proforma gross margin decline due to increased inventory reserves and changes in expense allocation.

Key Takeaways

Quanterix reported its Q3 2022 results with revenue flat compared to the prior year, excluding RADx. The company's proforma gross margin decreased due to increased inventory reserves and changes in expense allocation. A restructuring and business re-alignment plan was announced in August 2022 to enhance the potential of Simoa platforms.

Third quarter results aligned with expectations following the launch of an assay quality remediation program.

Revenue and gross margin grew quarter-over-quarter.

Consumable revenue declined as the company balanced demand with assay quality and process improvement initiatives.

Strong services revenue offset consumable revenue decline, driven by a collaboration agreement with Eli Lilly and Company.

Total Revenue
$26.6M
Previous year: $27.7M
-3.8%
EPS
-$0.38
Previous year: -$0.43
-11.6%
Gross Profit
$10.7M
Previous year: $14.2M
-25.1%
Cash and Equivalents
$344M
Previous year: $411M
-16.3%
Free Cash Flow
-$18.2M
Previous year: -$17.6M
+3.5%
Total Assets
$446M
Previous year: $511M
-12.8%

Quanterix

Quanterix

Forward Guidance

No forward guidance was provided in the press release.